Loading clinical trials...
Loading clinical trials...
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Conditions
Interventions
Esketamine (Intranasal Spray)
Duloxetine (Oral Antidepressant)
+3 more
Locations
109
United States
New Haven, Connecticut, United States
Miami, Florida, United States
Marietta, Georgia, United States
Iowa City, Iowa, United States
Wichita, Kansas, United States
Baltimore, Maryland, United States
Start Date
September 30, 2015
Primary Completion Date
October 28, 2017
Completion Date
October 28, 2017
Last Updated
April 29, 2025
NCT05377177
NCT07108257
NCT05710237
NCT06784388
NCT05045378
NCT06372834
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions